2021
DOI: 10.34172/apb.2022.029
|View full text |Cite
|
Sign up to set email alerts
|

Bioorganometallic Compounds as Novel Drug Targets against Schistosomiasis in Sub-Saharan Africa: An alternative to Praziquantel?

Abstract: Human schistosomiasis is a disease that mostly plagues the destitute of various tropical and sub-tropical countries, particularly in sub-Saharan Africa and South America. It has significant effects on various health and economic-related matters. Globally, the burden of schistosomiasis has been controlled with a single chemotherapeutic drug, Praziquantel, which has recently demonstrated several clinical issues, including its inability to destroy juvenile schistosome worms and drug resistance because of its exte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 98 publications
0
7
0
Order By: Relevance
“… 71 Reports of decreased PZQ sensitivity in some Schistosoma spp. strains are concerning; 72 however, new therapeutic strategies are in development. 72 , 74 , 75 …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“… 71 Reports of decreased PZQ sensitivity in some Schistosoma spp. strains are concerning; 72 however, new therapeutic strategies are in development. 72 , 74 , 75 …”
Section: Resultsmentioning
confidence: 99%
“…71 Treatment Praziquantel (PZQ) is considered the best available drug for schistosomiasis although its mechanism of action is not fully understood. 71,72 In the absence of standardized regimen, a single-day, oral dose of 40 mg/kg of PZQ is indicated by most authors as safe and effective for all Schistosoma spp, either in one or divided in two administrations, 71 with a reported cure rate of 77.1% for S. haematobium. 73 No correlation between cure rates and dosage of PZQ has been described for S. hematobium, 73 how-ever, especially in low-burden settings, higher dosages (up to 80 mg/kg), or a second PZQ dose after 15 days from the first, have been safely and effectively used.…”
Section: Diagnosismentioning
confidence: 99%
“…The large-scale and mono-therapeutic use of PZQ has raised many concerns for the treatment and control of schistosomiasis. The concerns mainly focused on the lack of activity against immature schistosome and the growing inclination to resistance of PZQ, which could be explanations to the poor cure rates and treatment failures in residents of high-risk regions [ 30 ]. Thus, it is of increasing importance to develop new drugs in the face of potential resistance to PZQ for the treatment of schistosomiasis, and the absence of an effective vaccine [ 31 ].…”
Section: Discussionmentioning
confidence: 99%
“…Metallodrugs open different and unique pathways for disease treatment, which traditional organic drugs cannot achieve due to drug resistance. 18 In addition, organometallic complexes also have a wide range of applications in materials, like solar cells, 19 electrocatalysts, 20 batteries, 21 etc. Given the great importance of organometallic complexes in both medical and industrial applications, much attention has been paid to the design of new organometallic complexes.…”
Section: ■ Introductionmentioning
confidence: 99%
“…In both cases, the metal is the focus of the metallodrug and tunes the 3D shape of the small organic ligands attached to the metal center. Metallodrugs open different and unique pathways for disease treatment, which traditional organic drugs cannot achieve due to drug resistance . In addition, organometallic complexes also have a wide range of applications in materials, like solar cells, electrocatalysts, batteries, etc.…”
Section: Introductionmentioning
confidence: 99%